Funding
← Back to your selection

5AM Ventures

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Jan 1, 2026
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$185M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1
Series C+1

By primary sector

Biotech3

By country

United States2
Switzerland1

Rounds

3 in this selection
Nouscom

Clinical-stage biotech developing neoantigen-based cancer immunotherapies.

€120MSeries D
Participant
Mendra

Develops and commercializes rare disease therapies using AI

$82MSeries A
Role not disclosed